

Fluzone® Influenza Virus Vaccine, 2004-2005 Formula

Catalog No. NR-10477

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Manufacturer:

Aventis Pasteur Inc.

Product Description:

NR-10477 is a split-virus vaccine prepared from influenza viruses A/New Caledonia/20/1999 (H1N1), A/Wyoming/3/2003 (H3N2) [an A/Fujian/411/2002 (H3N2)-like strain] and B/Jiangsu/10/2003 (a B/Shanghai/361/2002-like strain) that were predicted to circulate in the United States during the 2004 to 2005 influenza season.^{1,2}

NR-10477 was prepared from the extra-embryonic fluid of embryonated chicken eggs. The fluid containing the virus was harvested and inactivated with formaldehyde. The inactivated virus was concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus was then chemically disrupted using a nonionic surfactant (Triton® X-100) producing a split-virus. The split-virus was further purified by chemical means and suspended in sodium phosphate-buffered isotonic sodium chloride solution. Gelatin (0.05%) was added as a stabilizer. NR-10477 was formulated without preservatives but contains a trace amount of thimerosal (mercury derivative) from the manufacturing process.²

The hemagglutinin content was standardized according to U.S. Public Health Service requirements. Each 0.25 mL syringe contains the recommended ratio of 7.5 µg each of the hemagglutinin antigens from influenza viruses A/New Caledonia/20/1999 (H1N1), A/Wyoming/3/2003 (H3N2) and B/Jiangsu/10/2003.

Please note that this vaccine preparation is being released for research use only and not for human use. Vaccines produced for the 2004-2005 season are now past their expiration dates.

Material Provided:

Each syringe contains 0.25 mL of split-virus vaccine in phosphate-buffered saline containing 0.05% gelatin and a trace amount of thimerosal (≤ 0.5 µg mercury).

Packaging/Storage:

NR-10477 is packaged in a 0.25 mL pre-filled syringe. The product is provided on refrigerated bricks and should be stored at 2°C to 8°C immediately upon arrival. Do not freeze.

Citation:

Acknowledgment for publications should read "The following

reagent was obtained through BEI Resources, NIAID, NIH: Fluzone® Influenza Virus Vaccine, 2004-2005 Formula, NR-10477."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Harper, S. A., et al. "Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)." MMWR Recomm. Rep. 53 (2004): 1-40. PubMed: 15163927.
2. <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm127192.htm>

ATCC® is a trademark of the American Type Culture Collection.

